Home › Companies › Adaptive Biotechnologies Corporation › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings. Page generated November 20, 2026.
No official results are on file for this meeting: no Form 8-K tally (Item 5.07) from Adaptive Biotechnologies Corporation has been matched to it. The figures below are the funds’ own votes from Form N-PX. They are not the meeting result, so they are not used to judge dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Adaptive Biotechnologies Corporation in the interactive database Compare manager voting policies
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
316 asset managers disclosed a vote on at least one Adaptive Biotechnologies Corporation item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Adaptive Biotechnologies Corporation’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
99% of fund votes cast · no official result
Description as filed by funds: To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2029 annual meeting of shareholders: Katey Owen, PhD
The 99 asset managers below reported 50,610,991 for, 564,235 withheld, 6 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,495,475 | 0 | 6 | 10,067 | For |
| BlackRock | 6,627,973 | 0 | 0 | 0 | For |
| Fidelity | 3,795,586 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,671,643 | 0 | 0 | 0 | For |
| Invesco | 2,516,321 | 0 | 0 | 0 | For |
| Lord Abbett | 2,081,668 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,987,510 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,797,311 | 0 | 0 | 0 | For |
| ALGER FUNDS | 1,724,497 | 0 | 0 | 0 | For |
| TIAA | 1,536,717 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 1,145,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,131,615 | 0 | 0 | 0 | For |
| MFS | 1,072,505 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,008,596 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 774,600 | 0 | 0 | 0 | For |
| Aristotle Funds Series Trust | 687,260 | 0 | 0 | 0 | For |
| Principal | 555,306 | 0 | 0 | 0 | For |
| First Trust | 553,218 | 0 | 0 | 0 | For |
| Goldman Sachs | 534,382 | 0 | 0 | 0 | For |
| Hartford | 531,456 | 0 | 0 | 0 | For |
| Jackson National | 491,410 | 0 | 0 | 3,525 | For |
| Equitable | 471,234 | 0 | 0 | 0 | For |
| Brighthouse | 432,494 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 407,197 | 0 | 0 | 0 | For |
| MassMutual | 332,936 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
73% of fund votes cast · no official result
Description as filed by funds: To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2029 annual meeting of shareholders: Robert Hershberg, PhD, MD
The 99 asset managers below reported 37,187,617 for, 13,987,534 withheld, 81 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,495,400 | 0 | 81 | 10,067 | For |
| BlackRock | 6,627,973 | 0 | 0 | 0 | For |
| Fidelity | 3,791,847 | 0 | 0 | 3,739 | For |
| Columbia Threadneedle | 2,671,643 | 0 | 0 | 0 | For |
| Invesco | 2,516,321 | 0 | 0 | 0 | For |
| Lord Abbett | 2,081,668 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,987,510 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,138,958 | 0 | 0 | 658,353 | Mixed |
| ALGER FUNDS | 0 | 0 | 0 | 1,724,497 | Withhold |
| TIAA | 0 | 0 | 0 | 1,536,717 | Withhold |
| HARBOR FUNDS | 0 | 0 | 0 | 1,145,000 | Withhold |
| Charles Schwab | 1,131,615 | 0 | 0 | 0 | For |
| MFS | 0 | 0 | 0 | 1,072,505 | Withhold |
| Waddell & Reed | 0 | 0 | 0 | 1,008,596 | Withhold |
| OBERWEIS FUNDS | 0 | 0 | 0 | 774,600 | Withhold |
| Aristotle Funds Series Trust | 0 | 0 | 0 | 687,260 | Withhold |
| Principal | 0 | 0 | 0 | 555,306 | Withhold |
| First Trust | 0 | 0 | 0 | 553,218 | Withhold |
| Goldman Sachs | 491,692 | 0 | 0 | 42,690 | Mixed |
| Hartford | 531,456 | 0 | 0 | 0 | For |
| Jackson National | 491,410 | 0 | 0 | 3,525 | For |
| Equitable | 393,374 | 0 | 0 | 77,860 | Mixed |
| Brighthouse | 383,022 | 0 | 0 | 49,472 | Mixed |
| OPTIMUM FUND TRUST | 158,632 | 0 | 0 | 248,565 | Mixed |
| MassMutual | 332,936 | 0 | 0 | 0 | For |
Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
98% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,505,537 | 9 | 0 | 0 | For |
| BlackRock | 6,627,973 | 0 | 0 | 0 | For |
| Fidelity | 3,795,586 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,671,643 | 0 | 0 | 0 | For |
| Invesco | 2,516,321 | 0 | 0 | 0 | For |
| Lord Abbett | 2,081,668 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,987,510 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,797,311 | 0 | 0 | 0 | For |
| ALGER FUNDS | 1,724,497 | 0 | 0 | 0 | For |
| TIAA | 1,536,717 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 1,145,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,131,615 | 0 | 0 | 0 | For |
| MFS | 1,072,505 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,008,596 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 774,600 | 0 | 0 | 0 | For |
| Aristotle Funds Series Trust | 687,260 | 0 | 0 | 0 | For |
| Principal | 555,306 | 0 | 0 | 0 | For |
| First Trust | 553,218 | 0 | 0 | 0 | For |
| Goldman Sachs | 534,382 | 0 | 0 | 0 | For |
| Hartford | 531,456 | 0 | 0 | 0 | For |
| Jackson National | 494,935 | 0 | 0 | 0 | For |
| Equitable | 471,234 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 407,197 | 0 | 0 | 0 | For |
| MassMutual | 332,936 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST III | 311,564 | 0 | 0 | 0 | For |
Fund voting reports, all 96 managers: 50,894,688 for, 151 against, 15,022 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 29,993,708 | 0 | 0 | 0 | For |
| BlackRock | 5,437,531 | 2,375 | 0 | 0 | For |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4,994,048 | 0 | 0 | 0 | For |
| Invesco | 4,037,516 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,643,318 | 0 | 0 | 0 | For |
| Wellington | 3,113,267 | 0 | 0 | 0 | For |
| State Street | 2,942,148 | 4,618 | 0 | 0 | For |
| LORD, ABBETT & CO. LLC | 2,872,964 | 0 | 0 | 0 | For |
| T. Rowe Price | 2,664,545 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 2,572,254 | 0 | 0 | Against |
| FRED ALGER MANAGEMENT, LLC | 2,109,330 | 0 | 0 | 0 | For |
| Goldman Sachs | 1,671,182 | 0 | 0 | 0 | For |
| Amova Asset Management Co., Ltd. | 1,591,627 | 0 | 0 | 0 | For |
| Nuveen | 1,554,385 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,472,393 | 0 | 0 | 0 | For |
| Aristotle Atlantic Partners, LLC | 1,298,193 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,267,013 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 1,242,380 | 0 | 0 | 0 | For |
| Charles Schwab | 1,132,501 | 0 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1,072,505 | 0 | 0 | 0 | For |
| Aberdeen | 1,070,627 | 0 | 0 | 0 | For |
| Vanguard | 1,064,016 | 0 | 0 | 0 | For |
| Northern Trust | 1,021,011 | 0 | 0 | 0 | For |
| Blue Water Life Science Advisors, LP | 1,010,145 | 0 | 0 | 0 | For |
| DE Shaw | 979,645 | 0 | 0 | 0 | For |
Institutional-manager reports, all 238 managers: 93,576,909 for, 3,499,879 against, 76,365 withheld, 416 abstained, 32 not voted. Showing the 25 largest; every one is in the interactive database (link above).
100% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Brighthouse | 237,870 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 14,133 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 12,807 | 0 | 0 | 0 | For |
Fund voting reports, all 3 managers: 264,810 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ALGERT GLOBAL LLC | 109,505 | 0 | 0 | 0 | For |
| Integrated Quantitative Investments LLC | 18,150 | 0 | 0 | 0 | For |
| APG Asset Management US Inc. | 14,850 | 0 | 0 | 0 | For |
| Vinva Investment Management Ltd | 13,358 | 0 | 0 | 0 | For |
| Wilshire Advisors LLC | 5,105 | 0 | 0 | 0 | For |
| Convergence Investment Partners, LLC | 1,700 | 0 | 0 | 0 | For |
Institutional-manager reports, all 6 managers: 162,668 for.
Combines 3 wordings of this item as funds reported it.
99.9% of fund votes cast · no official result
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026; and
The 97 asset managers below reported 50,895,398 for, 1 against, 15,022 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 10,505,546 | 1 | 0 | 0 | For |
| BlackRock | 6,627,973 | 0 | 0 | 0 | For |
| Fidelity | 3,795,586 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,671,643 | 0 | 0 | 0 | For |
| Invesco | 2,516,321 | 0 | 0 | 0 | For |
| Lord Abbett | 2,081,668 | 0 | 0 | 0 | For |
| ARK ETF Trust | 1,987,510 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,797,311 | 0 | 0 | 0 | For |
| ALGER FUNDS | 1,724,497 | 0 | 0 | 0 | For |
| TIAA | 1,536,717 | 0 | 0 | 0 | For |
| HARBOR FUNDS | 1,145,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,131,615 | 0 | 0 | 0 | For |
| MFS | 1,072,505 | 0 | 0 | 0 | For |
| Waddell & Reed | 1,008,596 | 0 | 0 | 0 | For |
| OBERWEIS FUNDS | 774,600 | 0 | 0 | 0 | For |
| Aristotle Funds Series Trust | 687,260 | 0 | 0 | 0 | For |
| Principal | 555,306 | 0 | 0 | 0 | For |
| First Trust | 553,218 | 0 | 0 | 0 | For |
| Goldman Sachs | 534,382 | 0 | 0 | 0 | For |
| Hartford | 531,456 | 0 | 0 | 0 | For |
| Jackson National | 494,935 | 0 | 0 | 0 | For |
| Equitable | 471,234 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 407,197 | 0 | 0 | 0 | For |
| MassMutual | 332,936 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST III | 311,564 | 0 | 0 | 0 | For |
Showing the 25 largest of 97 asset managers. All 97 are in the interactive database (link above).
100% of fund votes cast · no official result
The 3 asset managers below reported 264,810 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Brighthouse | 237,870 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 14,133 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 12,807 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 159,697,221 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 6.58% |
| 2 | BlackRock | 4.15% |
| 3 | Fidelity | 2.38% |
| 4 | Columbia Threadneedle | 1.67% |
| 5 | Invesco | 1.58% |
| 6 | Lord Abbett | 1.30% |
| 7 | ARK ETF Trust | 1.24% |
| 8 | T. Rowe Price | 1.13% |
| 9 | ALGER FUNDS | 1.08% |
| 10 | TIAA | 0.96% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | VIKING GLOBAL INVESTORS LP | 18.78% |
| 2 | BlackRock | 3.41% |
| 3 | WESTFIELD CAPITAL MANAGEMENT CO LP | 3.13% |
| 4 | Invesco | 2.53% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.28% |
| 6 | Wellington | 1.95% |
| 7 | State Street | 1.85% |
| 8 | LORD, ABBETT & CO. LLC | 1.80% |
| 9 | T. Rowe Price | 1.67% |
| 10 | BNP Paribas Asset Management Holding S.A. | 1.61% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 29,993,708 | 18.78% | Schedule 13G, filed May 15, 2026 |
| Viking Global Entities | 29,993,708 | 18.78% | Proxy statement (DEF 14A), table as of April 1, 2026 |
| BlackRock | 13,303,025 | 8.33% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Subsidiaries and Divisions | 10,639,440 | 6.66% | Proxy statement (DEF 14A), table as of April 1, 2026 |
| Invesco | 4,450,066 | 2.79% | Form 13F, quarter ended March 31, 2026 |
| Wellington Management | 3,857,422 | 2.42% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 3,636,054 | 2.28% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 3,242,077 | 2.03% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,227,245 | 2.02% | Form 13F, quarter ended March 31, 2026 |
| Chad Robins | 3,122,794 | 1.96% | Proxy statement (DEF 14A), table as of April 1, 2026 |
Percentages above are of 159,697,221 shares outstanding, as reported by Adaptive Biotechnologies Corporation on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Adaptive Biotechnologies Corporation's shareholder meeting held June 5, 2026, in the 2025-2026 proxy season, 316 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,516 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds and managers cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Adaptive Biotechnologies Corporation’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Adaptive Biotechnologies Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Adaptive Biotechnologies (ADPT) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/adaptive-biotechnologies-corp/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.